AUSTIN, TX and DURHAM, NC, Dec. 02, 2021 (GLOBE NEWSWIRE) — Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease with three ongoing Phase 1 clinical trials, today announced its presentation at the TIGIT Therapies Digital Summit 2021 being held virtually December 7 – 9, 2021.
Presentation Details
Presentation Title: LIGHTing the Way for TIGIT Blockade in CPI Refractory Tumors
Presenter: Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive Officer
Date: December 9, 2021
Time: 9:30 a.m. EST
Location: https://tigit-therapies.com/
The presentation will be available for download on the Events & Presentations section of the company’s website and also will be available to registered participants of the TIGIT Therapies Digital Summit 2021.
About Shattuck Labs, Inc.
Shattuck Labs, Inc. (NASDAQ: STTK) is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck’s proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company’s SL-172154 (SIRPα-Fc-CD40L) program, which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in two Phase 1 trials. A second product candidate, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in solid tumors or lymphomas. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.
Investor Contact:
Conor Richardson
Senior Director, Finance & Investor Relations
Shattuck Labs, Inc.
InvestorRelations@shattucklabs.com
Media Contact:
Stephanie Ascher
Managing Director
Stern Investor Relations, Inc.
Stephanie.ascher@sternir.com
Toronto, Ontario--(Newsfile Corp. - July 8, 2024) - Optimind Pharma Corp. (CSE: OMND) ("Optimind" or…
Novel technology recognized for its groundbreaking design and patient-centric innovationSAN FRANCISCO--(BUSINESS WIRE)--Element Science, an innovative…
One Small Step Pairs Strangers With Opposing Political Beliefs for One-on-One Conversations, Not to Debate…
Positioning Navigate as a Leader in Comprehensive Wellbeing Solutions WEST DES MOINES, Iowa, July 8,…
SILVER SPRING, Md., July 8, 2024 /PRNewswire/ -- Today, the U.S. Food and Drug Administration…
SHENZHEN, China, July 8, 2024 /PRNewswire/ -- Goodix Technology today unveiled its Continuous Glucose Monitoring…